Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Michel Scherrmann

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Chemistry & Biodiversity|November 26, 2009
Transporters in absorption, distribution, and eliminationJean-Michel Scherrmann
Clinical Pharmacology and Therapeutics|August 18, 2020
Possible Role of ABCB1 in Lysosomal Accumulation of Azithromycin in COVID-19 TherapyJean-Michel Scherrmann
Expert Opinion on Drug Metabolism & Toxicology|August 23, 2006
Expression and function of multidrug resistance transporters at the blood-brain barriersJean-Michel Scherrmann
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques|December 17, 2003
Peptide vectors as drug carriersJamal Temsamani, Jean-Michel Scherrmann
Joint Bone Spine|October 28, 2006
Colchicine todayElisabeth Niel, Jean-Michel Scherrmann
Life Sciences|November 29, 2005
Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronideFanchon Bourasset, Jean-Michel Scherrmann
The Journal of Antimicrobial Chemotherapy|August 9, 2020
Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trialBruno Mégarbane, Jean-Michel Scherrmann
Journal of Clinical Pharmacology|May 21, 2020
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?Bruno Mégarbane, Jean-Michel Scherrmann
The AAPS Journal|December 17, 2008
Commentary: current advances and future directions for CNS deliveryCraig K Svensson, Jean-Michel Scherrmann
Biologie Aujourd'Hui|November 23, 2012
[Recent advances in quantitative proteomics as a sensitive tool to quantify drug transporters and drug metabolizing enzymes at the human blood-brain barrier]Aude Jacob, Xavier Declèves, Jean-Michel Scherrmann
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Chemistry & Biodiversity|November 26, 2009
Transporters in absorption, distribution, and eliminationJean-Michel Scherrmann
Clinical Pharmacology and Therapeutics|August 18, 2020
Possible Role of ABCB1 in Lysosomal Accumulation of Azithromycin in COVID-19 TherapyJean-Michel Scherrmann
Expert Opinion on Drug Metabolism & Toxicology|August 23, 2006
Expression and function of multidrug resistance transporters at the blood-brain barriersJean-Michel Scherrmann
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques|December 17, 2003
Peptide vectors as drug carriersJamal Temsamani, Jean-Michel Scherrmann
Joint Bone Spine|October 28, 2006
Colchicine todayElisabeth Niel, Jean-Michel Scherrmann
Life Sciences|November 29, 2005
Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronideFanchon Bourasset, Jean-Michel Scherrmann
The Journal of Antimicrobial Chemotherapy|August 9, 2020
Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trialBruno Mégarbane, Jean-Michel Scherrmann
Journal of Clinical Pharmacology|May 21, 2020
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?Bruno Mégarbane, Jean-Michel Scherrmann
The AAPS Journal|December 17, 2008
Commentary: current advances and future directions for CNS deliveryCraig K Svensson, Jean-Michel Scherrmann
Biologie Aujourd'Hui|November 23, 2012
[Recent advances in quantitative proteomics as a sensitive tool to quantify drug transporters and drug metabolizing enzymes at the human blood-brain barrier]Aude Jacob, Xavier Declèves, Jean-Michel Scherrmann
Pageof 12